Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 6 items

Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO study (AFT-19)

Aggarwal, Rahul , Heller, Glenn , Hillman, David , Xiao, Han ... - ASCO GU - J Clin Oncol - 2023

Abstract - Secondary-not-in-original - Primary - GU - AFT-19

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

George, Daniel , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ASCO GU - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - Alliance-A031203

Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)

Halabi, S. , Vogelzang, N. J. , Kornblith, A. B. , Archer, L. E. ... - ASCO GU - Genitourinary Cancers Symposium - 2009

Abstract - Secondary-not-in-original - Primary - GU - CALGB-9181 , CALGB-9182 , INT-0159

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance)

Halabi, S , Yang, Q. , Starr, Mark D , Brady, John C , Armstrong, A.J. ... - ASCO GU - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206

Harzstark, A. L. , Halabi, S. , Stadler, W. M. , Vaena, D. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

Smith, M. R. , Halabi, S. , Ryan, C. J. , Stadler, W. M. , Hussain, A. ... - ASCO GU - J Clin Oncol - 2013

Abstract - Primary - Primary - GU - CALGB-90202